BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 15588100)

  • 1. Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.
    Srivastava SK; Shefali S; Miller CN; Aceto MD; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2004 Dec; 47(26):6645-8. PubMed ID: 15588100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
    Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
    J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
    Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
    J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
    Zhang A; Xiong W; Hilbert JE; DeVita EK; Bidlack JM; Neumeyer JL
    J Med Chem; 2004 Apr; 47(8):1886-8. PubMed ID: 15055988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
    Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
    J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
    Ghirmai S; Azar MR; Polgar WE; Berzetei-Gurske I; Cashman JR
    J Med Chem; 2008 Mar; 51(6):1913-24. PubMed ID: 18298057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and SAR study of opioid receptor ligands: mono- and bis-indolomorphinans.
    Li F; Yin C; Chen J; Liu J; Xie X; Zhang A
    Chem Biol Drug Des; 2009 Oct; 74(4):335-42. PubMed ID: 19691470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
    Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
    J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
    Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
    Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-affinity carbamate analogues of morphinan at opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1508-11. PubMed ID: 17276685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist.
    Chauvignac C; Miller CN; Srivastava SK; Lewis JW; Husbands SM; Traynor JR
    J Med Chem; 2005 Mar; 48(5):1676-9. PubMed ID: 15743210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of quinolinomorphinan-4-ol derivatives as δ opioid receptor agonists.
    Ida Y; Nemoto T; Hirayama S; Fujii H; Osa Y; Imai M; Nakamura T; Kanemasa T; Kato A; Nagase H
    Bioorg Med Chem; 2012 Jan; 20(2):949-61. PubMed ID: 22197670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
    Lester PA; Traynor JR
    Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
    Grundt P; Jales AR; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2003 Apr; 46(8):1563-6. PubMed ID: 12672258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminothiazolomorphinans with mixed κ and μ opioid activity.
    Zhang T; Yan Z; Sromek A; Knapp BI; Scrimale T; Bidlack JM; Neumeyer JL
    J Med Chem; 2011 Mar; 54(6):1903-13. PubMed ID: 21351746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.